A fruitful learning did DC showcaseDespite the jet lag, the snow and the hazeFOURIER and SPIRE tried PCSK9Evolocumab and Bococizumab Stats looked fineEBBINGHAUS confirmed, Cognition doesn't failLowering lipids, a whole new trail.TAVR beat the scalpel in intermediate riskDEFINE FLAIR say bye to FFR; IFR makes procedure briskDECISION CTO proved that OMT is strongPCI only if symptoms go wrongFFR guided multi-vessel PCI is cleanCOMPARE ACUTE has clearly signaled it greenPost surgical, when LV become badLEVO CTS says Levosimendan addTreatment of VTE is not an easy guess'Rivoroxaban' says EINSTEIN CHOICEHDL mimetics and 'Inclisiran'Showed promise in Atherosclerosis in CARAT and ORIONA fruitful learning did DC showcaseDespite the jet lag, the snow and the hazeI learnt End-points, p value and all the MACEDidn't miss the cherry blossom, the Smithsonian aerospace.

(DC -- Washington DC; FOURIER -- Further cardiovascular outcome research with PCSK9 in subjects with elevated risk; SPIRE -- Studies of PCSK9 inhibition and reduction of vascular events; PCSK9 -- Proprotein convertase subtilisin/kexin type 9; EBBINGHAUS -- Evaluating PCSK9 binding antibody influence on cognitive health in high cardiovascular risk subjects; DECISION CTO -- Drug eluting stent implantation versus optimal medical treatment in patients with chronic total occlusion; OMT -- Optimal medical treatment; PCI -- Percutaneous coronary intervention; FFR -- Fractional flow reserve; IFR -- Instantaneous wave free ratio; COMPARE ACUTE -- Comparison between FFR guided revascularization versus conventional strategy in acute MI patients with multivessel disease; LEVO CTS -- Levosimendan in patients with left ventricular systolic dysfunction undergoing cardiac surgery requiring cardiopulmonary bypass; EINSTEIN CHOICE -- Reduced dose rivaroxaban in the long term prevention of recurrent symptomatic venous thromboembolism; CARAT -- CER 001 Atherosclerosis regression ACS trial; ORION 1 -- Inclisiran, a novel siRNA in LDLC reduction; MACE -- Major adverse cardiac events.)
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